Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Axogen (NASDAQ: AXGN) will present at the J.P. Morgan 2026 Healthcare Conference. Management is scheduled to present on Thursday, January 15, 2026 at 10:30 AM Pacific Standard Time. A live audio webcast will be available via the company’s investor relations site at ir.axogeninc.com.
This provides investors and analysts an opportunity to hear management commentary on recent developments and strategic priorities directly from company leadership.
Details
News Market Reaction – AXGN
On Dec 17, the day this news came out, AXGN closed 6.95% above the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Conference date
- January 15, 2026
- J.P. Morgan 2026 Healthcare Conference presentation
- Presentation time
- 10:30 AM PST
- Scheduled Axogen management presentation slot
Historical Context
-
FDA approved BLA for Avance nerve allograft with accelerated indications.
-
Announced participation in three late-2025 healthcare investor conferences.
-
Reported strong Q3 revenue growth, margin strength, and raised 2025 guidance.
-
Announced timing and access details for the Q3 2025 earnings release.
-
Outlined participation in four September 2025 investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference.
Axogen’s management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at ir.axogeninc.com.
About Axogen
Axogen (NASDAQ: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.
For more information, visit www.axogeninc.com.

Contact: Axogen, Inc. InvestorRelations@axogeninc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.